GSK's 5-in-1 meningococcal vaccine candidate has been accepted for FDA review as of April 16, 2024, aiming to simplify immunization by reducing injects; a decision is expected by February 14, 2025.
AI Assistant
GSK PLC
2024
6 K
Find Answers
Ask about any part of the document to get insights, explanations, or key details.